Biotech Values

[DewDiligence]

ACHN: Elvucitabine - This is the HIV nuke, which Dew has previously pointed out the flaws behind. I wouldn't expect much out of this one, but Mr. Kishbauch noted that ACHN is in discussions for 3 regional partnerships (one of which has advanced to a term-sheet) for the compound covering Asia, South Africa, and South America. ACHN expects a partnership for elvucitabine by year-end.

Unless elvucitabine can be marketed with a second nuke in a package that undercuts Truvada on pricing, which won’t be easy, I don’t see how it will gain much commercial traction in Third World countries. ACHN might be able to ink some “regional” deals for elvucitabine, but I doubt that they will be lucrative ones.